Loading…
Sanger sequencing versus INNO-LiPA® HBV PreCore assay for routine detection of precore and basal core promoter mutations in hepatitis virus B chronically infected patients
We compared the Sanger sequencing and the commercial INNO-LiPA® HBV assay for the routine detection of precore (PC) and basal core promoter (BCP) mutations of hepatitis B virus in chronically infected patients. The overall agreement rate between assays was 94.2% and 98.8% for the detection of PC and...
Saved in:
| Published in: | Diagnostic microbiology and infectious disease 2018-04, Vol.90 (4), p.277-279 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c380t-7ec998ecbf5cc4aa892a7d6db832f8b595d86c7c8ded54cf7dbdfc0462349ab13 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c380t-7ec998ecbf5cc4aa892a7d6db832f8b595d86c7c8ded54cf7dbdfc0462349ab13 |
| container_end_page | 279 |
| container_issue | 4 |
| container_start_page | 277 |
| container_title | Diagnostic microbiology and infectious disease |
| container_volume | 90 |
| creator | Alidjinou, E.K. Bocket, L. Pigot, V. Lambert, V. Hallaert, C. Canva, V. Hober, D. |
| description | We compared the Sanger sequencing and the commercial INNO-LiPA® HBV assay for the routine detection of precore (PC) and basal core promoter (BCP) mutations of hepatitis B virus in chronically infected patients. The overall agreement rate between assays was 94.2% and 98.8% for the detection of PC and BCP mutations, respectively.
•We compared Sanger sequencing and INNO-LiPA® HBV PreCore assay.•A very good agreement was observed between both methods.•INNO-LiPA assay was a little faster, while reagent cost was lower, for sequencing.•The sequencing can allow the detection of additional mutations. |
| doi_str_mv | 10.1016/j.diagmicrobio.2017.12.006 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1989553105</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0732889317304029</els_id><sourcerecordid>1989553105</sourcerecordid><originalsourceid>FETCH-LOGICAL-c380t-7ec998ecbf5cc4aa892a7d6db832f8b595d86c7c8ded54cf7dbdfc0462349ab13</originalsourceid><addsrcrecordid>eNqNkd1uFCEYhonR2LV6C4Z45MmMwPyBZ-1W2yabtok_p4SBb7ZsZmAFZpO9J-NFeGVlu9V46BH5kufjhfdB6B0lJSW0_bApjVXryerge-tLRmhXUlYS0j5DC8o7URDSkedoQbqKFZyL6gS9inFDCGWiJi_RCRMVJaLuFujnF-XWEHCEHzM4bd0a7yDEOeLrm5vbYmXvzn7_wlfn3_FdgKUPgFWMao8HH3Dwc7IOsIEEOlnvsB_wNoB-xJzBvYpqxI_jNvjJpxw0zUkd2Iitw_ewzUOyEe9syJnnWN8H76xW47jPwJDvBYMPELgUX6MXgxojvHk6T9G3z5--Lq-K1e3l9fJsVeiKk1R0oIXgoPuh0bpWigumOtOanlds4H0jGsNb3WluwDS1HjrTm0GTumVVLVRPq1P0_nhvfnWuJSY52ahhHJUDP0dJBRdNkytsMvrxiGYZMQYY5DbYSYW9pEQebMmN_NeWPNiSlMlsKy-_fcqZ-wnM39U_ejJwcQQg_3ZnIciocxMajM01J2m8_Z-cB6xKsqs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1989553105</pqid></control><display><type>article</type><title>Sanger sequencing versus INNO-LiPA® HBV PreCore assay for routine detection of precore and basal core promoter mutations in hepatitis virus B chronically infected patients</title><source>ScienceDirect Journals</source><creator>Alidjinou, E.K. ; Bocket, L. ; Pigot, V. ; Lambert, V. ; Hallaert, C. ; Canva, V. ; Hober, D.</creator><creatorcontrib>Alidjinou, E.K. ; Bocket, L. ; Pigot, V. ; Lambert, V. ; Hallaert, C. ; Canva, V. ; Hober, D.</creatorcontrib><description>We compared the Sanger sequencing and the commercial INNO-LiPA® HBV assay for the routine detection of precore (PC) and basal core promoter (BCP) mutations of hepatitis B virus in chronically infected patients. The overall agreement rate between assays was 94.2% and 98.8% for the detection of PC and BCP mutations, respectively.
•We compared Sanger sequencing and INNO-LiPA® HBV PreCore assay.•A very good agreement was observed between both methods.•INNO-LiPA assay was a little faster, while reagent cost was lower, for sequencing.•The sequencing can allow the detection of additional mutations.</description><identifier>ISSN: 0732-8893</identifier><identifier>EISSN: 1879-0070</identifier><identifier>DOI: 10.1016/j.diagmicrobio.2017.12.006</identifier><identifier>PMID: 29310947</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Basal core promoter ; Hepatitis B virus ; INNO-LiPA ; Mutations ; Precore ; Sanger sequencing</subject><ispartof>Diagnostic microbiology and infectious disease, 2018-04, Vol.90 (4), p.277-279</ispartof><rights>2017 Elsevier Inc.</rights><rights>Copyright © 2017 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c380t-7ec998ecbf5cc4aa892a7d6db832f8b595d86c7c8ded54cf7dbdfc0462349ab13</citedby><cites>FETCH-LOGICAL-c380t-7ec998ecbf5cc4aa892a7d6db832f8b595d86c7c8ded54cf7dbdfc0462349ab13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29310947$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Alidjinou, E.K.</creatorcontrib><creatorcontrib>Bocket, L.</creatorcontrib><creatorcontrib>Pigot, V.</creatorcontrib><creatorcontrib>Lambert, V.</creatorcontrib><creatorcontrib>Hallaert, C.</creatorcontrib><creatorcontrib>Canva, V.</creatorcontrib><creatorcontrib>Hober, D.</creatorcontrib><title>Sanger sequencing versus INNO-LiPA® HBV PreCore assay for routine detection of precore and basal core promoter mutations in hepatitis virus B chronically infected patients</title><title>Diagnostic microbiology and infectious disease</title><addtitle>Diagn Microbiol Infect Dis</addtitle><description>We compared the Sanger sequencing and the commercial INNO-LiPA® HBV assay for the routine detection of precore (PC) and basal core promoter (BCP) mutations of hepatitis B virus in chronically infected patients. The overall agreement rate between assays was 94.2% and 98.8% for the detection of PC and BCP mutations, respectively.
•We compared Sanger sequencing and INNO-LiPA® HBV PreCore assay.•A very good agreement was observed between both methods.•INNO-LiPA assay was a little faster, while reagent cost was lower, for sequencing.•The sequencing can allow the detection of additional mutations.</description><subject>Basal core promoter</subject><subject>Hepatitis B virus</subject><subject>INNO-LiPA</subject><subject>Mutations</subject><subject>Precore</subject><subject>Sanger sequencing</subject><issn>0732-8893</issn><issn>1879-0070</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNqNkd1uFCEYhonR2LV6C4Z45MmMwPyBZ-1W2yabtok_p4SBb7ZsZmAFZpO9J-NFeGVlu9V46BH5kufjhfdB6B0lJSW0_bApjVXryerge-tLRmhXUlYS0j5DC8o7URDSkedoQbqKFZyL6gS9inFDCGWiJi_RCRMVJaLuFujnF-XWEHCEHzM4bd0a7yDEOeLrm5vbYmXvzn7_wlfn3_FdgKUPgFWMao8HH3Dwc7IOsIEEOlnvsB_wNoB-xJzBvYpqxI_jNvjJpxw0zUkd2Iitw_ewzUOyEe9syJnnWN8H76xW47jPwJDvBYMPELgUX6MXgxojvHk6T9G3z5--Lq-K1e3l9fJsVeiKk1R0oIXgoPuh0bpWigumOtOanlds4H0jGsNb3WluwDS1HjrTm0GTumVVLVRPq1P0_nhvfnWuJSY52ahhHJUDP0dJBRdNkytsMvrxiGYZMQYY5DbYSYW9pEQebMmN_NeWPNiSlMlsKy-_fcqZ-wnM39U_ejJwcQQg_3ZnIciocxMajM01J2m8_Z-cB6xKsqs</recordid><startdate>201804</startdate><enddate>201804</enddate><creator>Alidjinou, E.K.</creator><creator>Bocket, L.</creator><creator>Pigot, V.</creator><creator>Lambert, V.</creator><creator>Hallaert, C.</creator><creator>Canva, V.</creator><creator>Hober, D.</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201804</creationdate><title>Sanger sequencing versus INNO-LiPA® HBV PreCore assay for routine detection of precore and basal core promoter mutations in hepatitis virus B chronically infected patients</title><author>Alidjinou, E.K. ; Bocket, L. ; Pigot, V. ; Lambert, V. ; Hallaert, C. ; Canva, V. ; Hober, D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c380t-7ec998ecbf5cc4aa892a7d6db832f8b595d86c7c8ded54cf7dbdfc0462349ab13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Basal core promoter</topic><topic>Hepatitis B virus</topic><topic>INNO-LiPA</topic><topic>Mutations</topic><topic>Precore</topic><topic>Sanger sequencing</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Alidjinou, E.K.</creatorcontrib><creatorcontrib>Bocket, L.</creatorcontrib><creatorcontrib>Pigot, V.</creatorcontrib><creatorcontrib>Lambert, V.</creatorcontrib><creatorcontrib>Hallaert, C.</creatorcontrib><creatorcontrib>Canva, V.</creatorcontrib><creatorcontrib>Hober, D.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Diagnostic microbiology and infectious disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alidjinou, E.K.</au><au>Bocket, L.</au><au>Pigot, V.</au><au>Lambert, V.</au><au>Hallaert, C.</au><au>Canva, V.</au><au>Hober, D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sanger sequencing versus INNO-LiPA® HBV PreCore assay for routine detection of precore and basal core promoter mutations in hepatitis virus B chronically infected patients</atitle><jtitle>Diagnostic microbiology and infectious disease</jtitle><addtitle>Diagn Microbiol Infect Dis</addtitle><date>2018-04</date><risdate>2018</risdate><volume>90</volume><issue>4</issue><spage>277</spage><epage>279</epage><pages>277-279</pages><issn>0732-8893</issn><eissn>1879-0070</eissn><abstract>We compared the Sanger sequencing and the commercial INNO-LiPA® HBV assay for the routine detection of precore (PC) and basal core promoter (BCP) mutations of hepatitis B virus in chronically infected patients. The overall agreement rate between assays was 94.2% and 98.8% for the detection of PC and BCP mutations, respectively.
•We compared Sanger sequencing and INNO-LiPA® HBV PreCore assay.•A very good agreement was observed between both methods.•INNO-LiPA assay was a little faster, while reagent cost was lower, for sequencing.•The sequencing can allow the detection of additional mutations.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>29310947</pmid><doi>10.1016/j.diagmicrobio.2017.12.006</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0732-8893 |
| ispartof | Diagnostic microbiology and infectious disease, 2018-04, Vol.90 (4), p.277-279 |
| issn | 0732-8893 1879-0070 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1989553105 |
| source | ScienceDirect Journals |
| subjects | Basal core promoter Hepatitis B virus INNO-LiPA Mutations Precore Sanger sequencing |
| title | Sanger sequencing versus INNO-LiPA® HBV PreCore assay for routine detection of precore and basal core promoter mutations in hepatitis virus B chronically infected patients |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T18%3A12%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sanger%20sequencing%20versus%20INNO-LiPA%C2%AE%20HBV%20PreCore%20assay%20for%20routine%20detection%20of%20precore%20and%20basal%20core%20promoter%20mutations%20in%20hepatitis%20virus%20B%20chronically%20infected%20patients&rft.jtitle=Diagnostic%20microbiology%20and%20infectious%20disease&rft.au=Alidjinou,%20E.K.&rft.date=2018-04&rft.volume=90&rft.issue=4&rft.spage=277&rft.epage=279&rft.pages=277-279&rft.issn=0732-8893&rft.eissn=1879-0070&rft_id=info:doi/10.1016/j.diagmicrobio.2017.12.006&rft_dat=%3Cproquest_cross%3E1989553105%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c380t-7ec998ecbf5cc4aa892a7d6db832f8b595d86c7c8ded54cf7dbdfc0462349ab13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1989553105&rft_id=info:pmid/29310947&rfr_iscdi=true |